The interleukin-2 fusion protein, DAB sub(389)IL-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells

DAB sub(389)IL-2 is a genetically engineered fusion protein that reduces human immunodeficiency virus type 1 (HIV-1) replication in activated, interleukin (IL)-2 receptor (IL-2R)-expressing human peripheral blood mononuclear cells (PBMC). The level of infectious virus released by cultured PBMC after...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1997-04, Vol.175 (4), p.790-794
Main Authors: Zhang, L J, Waters, CA, Poisson, L R, Estis, L F, Crumpacker, C S
Format: Article
Language:English
Subjects:
human immunodeficiency virus 1
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:DAB sub(389)IL-2 is a genetically engineered fusion protein that reduces human immunodeficiency virus type 1 (HIV-1) replication in activated, interleukin (IL)-2 receptor (IL-2R)-expressing human peripheral blood mononuclear cells (PBMC). The level of infectious virus released by cultured PBMC after treatment with DAB sub(389)IL-2 was measured by a quantitative microculture assay. The inhibition of p24 antigen production was also evaluated in cultures that differed in duration of infection and activation state. Although the activation state of the cell and the time of DAB sub(389)IL-2 addition to the cultures influenced its anti-HIV activity, DAB sub(389)IL-2 treatment decreased levels of infectious HIV-1 to 0.1%-6.5% of untreated cell levels. DAB sub(389)IL-2 also decreased p24 antigen expression to 10%-48% of controls, even when added as late as 8 days after acute infection. Mutational variants of DAB sub(389)IL-2 that lack catalytic activity or IL-2R binding are without anti-HIV activity.
ISSN:0022-1899